MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598647 | Name: Anthrarobin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Anthrarobin is an antipsoriatic.

Chemical Structure

Anthrarobin
Anthrarobin
CAS#577-33-3

Theoretical Analysis

MedKoo Cat#: 598647

Name: Anthrarobin

CAS#: 577-33-3

Chemical Formula: C14H10O3

Exact Mass: 226.0630

Molecular Weight: 226.23

Elemental Analysis: C, 74.33; H, 4.46; O, 21.22

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Anthrarobin; NSC 60015; NSC-60015; NSC60015;
IUPAC/Chemical Name
anthracene-1,2,10-triol
InChi Key
TZIQWQARHPGHIG-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H10O3/c15-12-6-5-10-11(14(12)17)7-8-3-1-2-4-9(8)13(10)16/h1-7,15-17H
SMILES Code
Oc1c(cccc2)c2cc3c(O)c(O)ccc31
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 226.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: SCHALTEGGER H, KREBS A, KUSKE H. [ANALYSIS OF THE STRUCTURE OF ANTHRAROBIN AND ITS ACTION IN PSORIASIS]. Dermatologica. 1965;130:348-57. German. PubMed PMID: 14331066. 2: Kim YH, Moody JD, Freeman JP, Brezna B, Engesser KH, Cerniglia CE. Evidence for the existence of PAH-quinone reductase and catechol-O-methyltransferase in Mycobacterium vanbaalenii PYR-1. J Ind Microbiol Biotechnol. 2004 Dec;31(11):507-16. Epub 2004 Nov 11. PubMed PMID: 15549609. 3: HAXTHAUSEN H, SCHOU SA. [Anthrarobin and substitutes]. Ugeskr Laeger. 1950 May 4;112(18):631-2. Undetermined Language. PubMed PMID: 15424984. 4: Keller-Melchior R, Bräuninger W. Allergic contact dermatitis from anthrarobin. Contact Dermatitis. 1995 Nov;33(5):361. PubMed PMID: 8565505. 5: SIDI E, HINCKY M. [Comparative action of various reducing agents in the local treatment of psoriasis; clinical experimentation on anthrarobin]. Concours Med. 1956 May 19;78(20):2342-50. French. PubMed PMID: 13330357. 6: Sheu SY, Chiang HC. Inhibition of xanthine oxidase by hydroxylated anthraquinones and related compounds. Anticancer Res. 1997 Sep-Oct;17(5A):3293-7. PubMed PMID: 9413162. 7: Lateef M, Azhar A, Siddiqui BS, Zarina S, Uddin N, Anwar MF, Siddiqui K, Azhar KF, Iqbal L, Mehmood R, Perveen S. New anthrarobin acyl derivatives as butyrylcholinesterase inhibitors: synthesis, in vitro and in silico studies. Heliyon. 2017 Jul 10;3(7):e00350. doi: 10.1016/j.heliyon.2017.e00350. eCollection 2017 Jul. PubMed PMID: 28725871; PubMed Central PMCID: PMC5506883. 8: Krebs A, Schaltegger H Sr, Schaltegger A Jr. Structure specificity of the antipsoriatic anthrones. Br J Dermatol. 1981 Aug;105 Suppl 20:6-11. PubMed PMID: 7284267. 9: Hiipakka RA, Zhang HZ, Dai W, Dai Q, Liao S. Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol. 2002 Mar 15;63(6):1165-76. PubMed PMID: 11931850. 10: Ríos-Santamarina I, García-Domenech R, Gálvez J, Cortijo J, Santamaria P, Morcillo E. New bronchodilators selected by molecular topology. Bioorg Med Chem Lett. 1998 Mar 3;8(5):477-82. PubMed PMID: 9871602. 11: Churchill MR, Keil KM, Bright FV, Pandey S, Baker GA, Keister JB. Linkage and redox isomerism in ruthenium complexes of catecholate, semiquinone, and o-acylphenolate ligands derived from 1,2-dihydroxy-9,10-anthracenedione (alizarin) and related species: syntheses, characterizations, and photophysics. Inorg Chem. 2000 Dec 11;39(25):5807-16. PubMed PMID: 11151384. 12: Savić TD, Janković IA, Šaponjić ZV, Čomor MI, Veljković DŽ, Zarić SD, Nedeljković JM. Surface modification of anatase nanoparticles with fused ring catecholate type ligands: a combined DFT and experimental study of optical properties. Nanoscale. 2012 Mar 7;4(5):1612-9. doi: 10.1039/c2nr11501h. Epub 2012 Feb 6. PubMed PMID: 22310856.

View History

Anagrelide

Anagrelide

Featured